Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Status:
Completed
Trial end date:
2017-07-10
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous
(SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants
with active, moderate to severe Eosinophilic Esophagitis (EoE).
The secondary objectives of the study are:
- To assess the safety, tolerability, and immunogenicity of SC doses of dupilumab in adult
participants with active, moderate to severe EoE
- To assess the effect of dupilumab on esophageal eosinophilic infiltration
- To evaluate the pharmacokinetics (PK) of dupilumab in adult participants with EoE